标题
GLP-1 Receptor Agonists and Kidney Protection
作者
关键词
-
出版物
Medicina-Lithuania
Volume 55, Issue 6, Pages 233
出版商
MDPI AG
发表日期
2019-05-31
DOI
10.3390/medicina55060233
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
- (2018) Chengshi Wang et al. PLoS One
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
- (2018) Jordan Rowlands et al. Frontiers in Endocrinology
- Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney
- (2017) Dilip K. Deb et al. FASEB JOURNAL
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients
- (2017) Phisitt Vejakama et al. BMC Nephrology
- Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
- (2016) Karly C. Sourris et al. CURRENT DRUG TARGETS
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Predictors of chronic kidney disease in type 2 diabetes
- (2016) Salvatore De Cosmo et al. MEDICINE
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
- (2016) Lin Wang et al. Scientific Reports
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
- (2015) Melanie J. Davies et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
- (2015) Sander Kooijman et al. DIABETOLOGIA
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes
- (2015) Bernt Johan von Scholten et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
- (2015) Mark M Smits et al. BMJ Open
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes
- (2014) Salvatore De Cosmo et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- The effect of RAAS blockade on the progression of diabetic nephropathy
- (2013) Sara S. Roscioni et al. Nature Reviews Nephrology
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Pathologic Classification of Diabetic Nephropathy
- (2010) T. W. C. Tervaert et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
- (2009) Nancy A. Thornberry et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
- (2009) T. Ninomiya et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation